A

Amgen

Makes biotech medicines for serious illnesses

Executive Director U.S. Medical Affairs Cardiovascular Portfolio Lead

Full-TimeUpdated on 10/24/2026
$325.3k - $440.1k/yr+ Annual bonus + Stock-based long-term incentives
Expert
Bachelor's, Master's, PhD, MD
Thousand Oaks, CA, USA
Remote
Biology & Biotech

About the job

Requirements
  • A doctorate degree and 6 years of medical affairs or cardiovascular experience, or a master's degree and 10 years of medical affairs or cardiovascular experience, or a bachelor's degree and 12 years of medical affairs or cardiovascular experience.
  • At least 6 years of managerial experience directly managing people and/or leadership experience leading teams, projects, programs, or directing resource allocation.
  • In-depth experience developing and executing U.S. Medical Affairs strategies across a portfolio or multiple assets, preferably within cardiovascular disease.
  • Experience translating clinical development and evidence-generation strategy into integrated U.S. cardiovascular portfolio and asset-level medical priorities.
  • MD or another advanced clinical or scientific degree.
  • Experience with both inline and pipeline launches in the U.S.
  • At least 10 years of biopharmaceutical industry experience across Medical Affairs, Clinical Development, or related functions.
  • Demonstrated experience leading U.S. product launches, lifecycle management, and portfolio strategy.
  • Broad scientific and clinical knowledge across cardiovascular disease, including atherosclerotic cardiovascular disease and lipid management.
  • Strong knowledge of U.S. evidence generation, scientific communication, congress planning, field medical strategy, and external engagement.
  • Experience developing above-brand disease-state strategies and applying implementation science approaches to close evidence-to-practice gaps across healthcare systems.
  • Experience leading across multiple assets, indications, or cardiovascular disease areas and establishing portfolio-level priorities and synergies.
  • Demonstrated ability to collaborate effectively with adjacent medical teams, including Obesity Medical, on shared scientific and patient-care priorities.
  • Experience partnering with U.S. professional societies, advocacy organizations, academic institutions, health systems, payers, and other external cardiovascular stakeholders.
  • Experience translating global strategies into integrated U.S. portfolio and asset plans.
  • Expertise in medical education, insight generation, and stakeholder engagement within applicable legal, regulatory, and compliance requirements.
  • Strong financial, budgeting, governance, prioritization, and resource management capabilities.
  • Experience building and developing high-performing Medical Affairs and/or Field Medical teams.
  • Strong strategic thinking, executive communication, change leadership, and matrix leadership skills.
  • Experience leveraging digital and AI-enabled solutions to improve medical engagement and operational effectiveness.
  • Deep understanding of the U.S. healthcare environment, clinical guidelines, reimbursement, access, quality measures, population health, and policy landscape.
  • Knowledge of Good Clinical Practice, U.S. regulatory requirements, and Medical Affairs compliance standards.
Responsibilities
  • Serve on the U.S. Medical Affairs leadership team to shape enterprise and cardiovascular strategic priorities.
  • Lead the development and execution of an integrated U.S. medical strategy across established and pipeline cardiovascular assets, including atherosclerotic cardiovascular disease, dyslipidemia, and related cardiovascular priorities.
  • Maintain strategic and executional leadership for Repatha while building a coherent portfolio approach for future cardiovascular programs.
  • Translate global asset and disease-area strategies into differentiated U.S. priorities based on clinical practice, guidelines, policy, access, health-system, and patient needs.
  • Identify portfolio-level and above-brand synergies across implementation science, evidence generation, scientific platforms, stakeholder engagement, medical education, congresses, field deployment, and operational capabilities.
  • Partner with U.S. Field Medical, Implementation Science, Clinical Development, Commercial, Access, Regulatory, Legal, Compliance, and Global Medical Affairs to align scientific and medical objectives across the cardiovascular portfolio.
  • Lead development of an above-brand cardiovascular strategy across the U.S. Medical Affairs team to address shared disease-state priorities, prevention, diagnosis, guideline implementation, care pathways, health equity, and system-level barriers beyond individual assets.
  • Collaborate with Implementation Science colleagues to identify barriers and facilitators to evidence-based cardiovascular care; design, test, evaluate, sustain, and scale interventions; and translate findings into portfolio strategy, field execution, and health-system partnerships.
  • Work closely with the Obesity Medical team on shared scientific priorities, evidence-generation opportunities, field insights, education, and external engagement at the intersection of obesity and cardiovascular risk, while maintaining clear portfolio ownership and governance.
  • Lead and develop U.S. Medical Affairs team members to drive excellence in evidence generation, scientific communication, medical education, congress planning, and stakeholder engagement.
  • Oversee an integrated U.S. congress and professional society strategy across cardiology, lipidology, primary care, and other relevant cardiovascular specialties, coordinating engagement with the Obesity Medical team when appropriate.
  • Drive differentiated U.S. scientific narratives, core medical content, publications, educational initiatives, and external engagement plans at portfolio and asset levels.
  • Engage experts, professional societies, advocacy organizations, integrated delivery networks, health systems, payers, quality organizations, and academic networks to strengthen scientific partnerships and address cardiovascular care gaps.
  • Support independent medical education and other compliant educational initiatives for physicians, nurses, pharmacists, advanced practice professionals, and patient-focused stakeholders.
  • Partner with Field Medical leadership to establish portfolio- and asset-level engagement priorities, strengthen medical science liaison capabilities, and convert field insights into actionable medical strategy.
  • Ensure compliant capture, synthesis, communication, and use of scientific insights across cardiovascular diseases, assets, field interactions, congresses, advisory activities, and external partnerships.
  • Lead U.S. launch readiness and lifecycle management for marketed and pipeline cardiovascular assets, including sequencing priorities and balancing resources across the portfolio.
  • Provide medical input into U.S. access, reimbursement, quality improvement, policy, prevention, and value-based partnership priorities across cardiovascular disease.
  • Advance clinical, real-world, health economics, implementation science, population health, and outcomes research to address U.S. cardiovascular evidence gaps, accelerate translation of evidence into practice, and demonstrate portfolio impact.
  • Promote integrated, multidisciplinary approaches to cardiovascular risk reduction and coordinate with the Obesity Medical team on shared patient needs.
  • Lead resource planning, prioritization, governance, and budget allocation across U.S. Medical Affairs cardiovascular portfolio objectives.
  • Drive innovation and operational excellence, including responsible use of artificial-intelligence-enabled solutions across insight generation, medical engagement, congress planning, stakeholder management, and operations.
  • Recruit, develop, and mentor a high-performing U.S. Medical Affairs team while fostering a collaborative, inclusive, and patient-focused culture.
  • Strengthen Amgen’s reputation as a trusted, science-driven, patient-focused partner within the U.S. cardiovascular community.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.